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ABSTRACT 
Background: Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria have 
becoming increasingly prevalent in the US in the past decade. Klebsiella pneumoniae presents 
significant clinical challenges, as they are frequently misclassified and highly resistant to all 
commonly available antimicrobials, leading to delay in treatment and rapid spread in the 
hospital. With its high sensitivity and significantly reduced price, whole genome sequencing 
(WGS) has been considered a viable approach to help facilitate the identification of KPC-
positive K. pneumonia from patient isolates from gastrointestinal endoscopy. However, evidence 
for its cost-effectiveness is lacking, which is of high public health significance. 
Objective: to compare the cost-effectiveness of WGS and the standard of care (SOC, 
high-level disinfection), in the detection and prevention of KPC-positive K. pneumonia.  
Methods: A hypothetical cohort of 1000 patients was simulated for ten years using a 
four-state Markov model. KPC-positive K. pneumoniae-caused infection-related healthcare costs 
and quality-adjusted life year (QALY) were estimated for both the WGS strategy and the SOC 
strategy. 
Results: The base case analysis showed that with the infection rate assumed to be 1% 
and the cost of WGS at $100 per test, the ten-year mean cost for a patient in the WGS strategy 
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was $3,281.80 with 8.0819 QALYs gained, while the total cost for the SOC strategy was 
$4,583.50 with 8.0507 QALYs gained. Under these conditions, the SOC strategy was dominated 
by the WGS strategy. One-way sensitivity analysis and probabilistic sensitivity analysis (PSA) 
revealed that WGS remained economically dominant compared to SOC with the willingness-to-
pay level at $50,000. 
Conclusion: In summary, the WGS strategy is more cost effective in identifying PC-
positive K. pneumonia than SOC strategy.  
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1.0  INTRODUCTION 
Since the innovation of the next generation sequencing (NGS) technologies and the subsequent 
drop in sequencing costs, there has been enthusiasm for the use of whole genome sequencing in 
various clinical settings. NGS is advantageous over traditional Sanger sequencing because NGS 
is massively parallel, sequencing millions of short DNA fragments in a high throughput manner. 
As a result, NGS is significantly faster and cheaper than classical methods. Thus, it is anticipated 
that whole genome sequencing can be readily performed, leading to improvement in diagnostic 
sensitivities and decision-making in precision medicine. Therefore whole genome sequencing 
will not only enhance patient care, but also reduce the skyrocketing healthcare costs through 
prevention and more effective treatment in the long-term. However, concerns remain that there is 
not sufficient evidence demonstrating the effectiveness of genetic testing and the high cost and 
lack of reimbursement could be the largest barrier to incorporating genetic testing into routine 
clinical practice 2. 
1.1 EPIDEMIOLOGY OF KPC-POSITIVE K. PNEUMONIAE 
Recent epidemiological studies suggest that there has been an increasing trend in carbapenem-
resistant Enterobacteriaceae in the US in the past decade 3 4. Carbapenem-resistance is conferred 
by organisms harboring carbapenemase, among which Klebsiella pneumoniae carbapenemase is 
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the most common one in the US 3. The initial outbreak of Carbapenem-resistant K pneumoniae 
occurred in hospitals in New York city and quick spread to states in the Mid-Atlantic region 5. 
Nationwide SENTRY surveillance data from 2007 to 2009 revealed that Mid-Atlantic states 
continued to show a significantly higher frequency of KPC-positive organisms than other regions 
in the US: 28.6% in Mid-Atlantic vs 5.5% nationwide 6. In addition, KPC-positive K. 
pneumoniae isolates used in the SENTRY study were found from bloodstream infections (BSI, 
respiratory tract infections (RTI), urinary tract infections (UTI), and skin and skin structure 
infections and other sites of infection (SSSI/O), where BSI was the primary source of infection6.   
1.2 RESISTANCE OF KPC-POSITIVE K. PNEUMONIAE 
KPC-positive K. pneumoniae isolates are essentially resistant to all the commonly available 
antimicrobials. The only remaining options are colistin and tigecycline 6. However, these agents 
are associated with serious disadvantages, such as nephrotoxicity due to dosing challenges, 
development of resistance, safety concerns6. Therefore it is critically important that KPC-
positive K. pneumoniae isolates be identified in a timely and accurate manner to effectively 
control the spread. Antimicrobial susceptibility tests are routinely performed in clinical 
microbiological laboratories to identify KPC-positive K. pneumoniae. During testing minimal 
inhibitory concentrations (MICs) for each antimicrobial are determined for the isolate. If any 
MICs fall into the susceptible range, further testing such as PCR will be employed. Although 
susceptibility testing has been implemented on a regular basis, clinical laboratories still face 
significant challenges to accurately detect KPC-positive K. pneumoniae. Detection accuracy in 
part depends on the choice of carbapenem and the associated screening methods. Different 
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carbapenem agents have different MICs and unique sensitivity and specificity profiles. 
Moreover, different expression levels of carbapenemase and the presence of other extended-
spectrum β-lactamases also add another layer of complexity to accurate detection. Even with the 
updated Clinical Laboratory Standards Institute (CLSI) interpretative criteria, it is difficult to 
differentiate between KPC-positive K. pneumoniae and other extended-spectrum β-lactamases 
producing organisms, the latter of which may be treated with carbapenem 7. 
Recently researchers at the University of Pittsburgh reported the detection of   KPC-
positive K. pneumonia from patients undergoing endoscopic retrograde 
cholangiopancreatography from a single hospital 1. In addition to routine detection approaches, 
such as antimicrobial susceptibility test and PCR analysis, the authors also employed novel 
methods, including comparative whole genome sequence analysis and plasmid analysis. Whole 
genome sequence analysis was carried out for both patient and endoscope isolates, which 
allowed the authors to subsequently compare single nucleotide polymorphisms (SNPs) between 
patient and endoscope samples and identify two clusters among the samples. Further analysis 
based on whole plasmid sequencing provided high-resolution genetic signatures enabling the 
tracking of KPC gene transmission and reconstruction of the outbreak.  
1.3 HOSPITAL ACQUIRED INFECTION 
Improvement in patient safety and reduction of hospital acquired infections has been a priority of 
the department of health and human services 8. A multistate point-prevalence survey of health 
care–associated infections conducted by cdc showed that 4.0% of inpatients in acute care 
hospitals in the US had at least 1 health care–associated infection it is estimated that there were 
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about 721,800 infections in 2011 9. Klebsiella pneumoniae and k. Oxytoca was the third most 
common pathogen causing these infections.  
Bacteremia is a form of infection where there are bacteria present in the bloodstream. 
Majority of KPC-positive K. pneumoniae infections are bacteremia. Bacteremia is a serious 
infection that can lead to life-threatening events. Patients with bacteremia not only have higher 
short-term mortality but also have higher long-term mortality rates 10, reduced quality of life 
after hospital discharge 11,12, and significantly higher health care costs 13. A more accurate and 
faster turnaround whole genome sequencing (WGS) strategy-detecting infection in order to 
prevent a potential outbreak (by reducing the number of new cases infected) was compared with 
the standard of care using cost-effectiveness framework in this study.   
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2.0  METHODS 
2.1 DECISION TREE 
A decision tree with two Markov subtrees was developed with the Treeage Pro software 
(Treeage Software Inc., Williamstown, MA) (Figure 1). We compared two strategies with the 
decision trees. The two strategies were using whole genome sequencing (WGS) to detect hospital 
acquired infection vs the standard of care (SOC) in the case of potential infection of KPC-
positive K. pneumoniae from patients undergoing endoscopic retrograde 
cholangiopancreatography (Figure 1). Markov models (described below) were used in both 
branches (WGS vs SOC) to estimate costs and quality-adjusted life years (QALYs). These 
outcomes come from the initial infected patient and those who get subsequent infection from this 
patient. Future costs and benefits were discounted at an annual rate of 3%. 
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Figure 1. The cost-effectiveness decision model. 
2.2 MARKOV SUBTREES 
Markov subtrees were developed using the Treeage Pro software (Treeage Software Inc., 
Williamstown, MA) to simulate disease progression and estimate costs and quality-adjusted life 
years (QALYs) of patients with suspected infection of Klebsiella pneumoniae from using 
endoscopes in the University of Pittsburgh Medical Center (UPMC) Presbyterian Hospital and 
patients without infection. Since the mortality rate in the first three months of patients infected 
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with bacteremia is very different from that after three months we used cycle length of three-
month in the Markov subtrees to capture the different mortality rates. 
There are four health states in the Markov subtree for patients who get infected with 
bacteremia (represented by “BAC Markov” in Figure 1): 1) healthy state; 2) bacteremia state; 3) 
post-bacteremia state; 4) death state (Figure 2). We defined the post-bacteremia state because 
sepsis survivors (a similar disease) usually experience residual physical, cognitive and 
psychosocial problems lasting from 5 to 15 years after intensive care unit (ICU) discharge. 
During this post-bacteremia state the rate of a major illness recurring and/or mortality is also 
increased 14. While the Markov model for patients who are not infected with bacteremia 
(represented by “NO BAC Markov” in Figure 1) only has two states: live and death. Both 
Markov subtrees were ½ cycle corrected.  
Since the cycle length is 3 months, four cycles are needed to represent a whole year of the 
four states. We modeled a 10-year span, and 40 cycles were needed. Age-specific probabilities 
were applied as the transition probabilities in the first year (first 4 cycles) were different from the 
next year, and so on. 
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Figure 2. Markov subtree structure. 
Markov subtree (“BAC Markov”) structure for patients who are infected with bacteremia. 
Patients occupied one state at a time and transitioned every three months according to transition 
probabilities.  
2.3 LIFE EXPECTANCIES AND MORTALITY RATES 
The age-specific probability of dying was used to calculate the transition probability from 
healthy state to death. The baseline probability of dying of patients was taken from 2011 US life 
table. The transition probability from healthy state to death was estimated by directly using the 
values in the life table from age 60. 
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The mortality rate associated with patients with infection of Klebsiella pneumoniae from 
our data was calculated according to the DEALE method 15. There are several steps involved in 
this method. First, annual population mortality rate (μ���pop) was calculated as reciprocal of life
expectancy of the simulated population using US life table. Second, μ���pop was converted to 3-
month mortality rate (µ� 3mpop). Third, the annual compound mortality rate (for patients with 
infection of Klebsiella pneumoniae was calculated from our hospital data using this relationship  
Equation 1 
μ���C = - 1
𝑡𝑡
ln(S)
Equation 2 
  µ�3mD = µ�3mC - µ�3mpop        
In the equation 1, the average annual compound mortality rate (µ�C) can be expressed as a 
function of time of survival (t) and probability of survival. Fourth, µ�C was converted to 3-month 
compound mortality rate (µ�3mC). In the equation 2, the 3-month bacteremia-specific mortality 
rate (µ�3mD) is the difference between 3-month compound mortality rate (µ�3mC) and 3-month 
population mortality rate (µ�3mpop). The last step was conversion of the 3-month bacteremia-
specific mortality rate into probability. 
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2.4 PREVALENCE ESTIMATES  
Since the hospital is located in the Mid-Atlantic geographic region, with the highest prevalence 
of KPC-positive K. pneumoniae in the nation at 28% and the percentage of its resistance to high-
level disinfection is higher than 6%, the transition probability from healthy state to bacteremia 
state was assumed at 1% (assume both the prevalence and percentage of resistance are higher in 
the hospital setting).6 In the one-way sensitivity analysis and probabilistic sensitivity analysis, a 
range from 0.1% to 5% was used for the prevalence of KPC-positive K. pneumoniae (Table 2).  
2.5 SENSITIVITY AND SPECIFICITY 
The point estimates of sensitivity and specificity of the WGS test were obtained from Kosar et 
al.19 These values represent the “intrinsic” detection capability of the WGS test, namely 
accuracy, which is critical to prevention of a outbreak by limiting the number of new cases 
infected. In the WGS strategy branch, both sensitivity and specificity along with prevalence were 
used to determine probability of a positive test (pPositiveTest in Figure 1), probability of 
bacteremia infection after a positive test (pBACafter_positive_test in Figure 1), and probability 
of bacteremia infection after a negative test (pBACafter_negative_test in Figure 1). The three 
equations are listed here: 
Equation 3 
pPositiveTest=Prevalence*Sensitivity+(1-Prevalence)*(1-Specificity)        
Equation 4 
pBACafter_positive_test=
Prevalence∗Sensitivity(Prevalence∗Sensitivity+(1−Prevalence)∗(1−Specificity))
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Equation 5 
pBACafter_negative_test=
Prevalence∗(1−Sensitivity)(Prevalence∗(1−Sensitivity)+(1−Prevalence)∗Specificity)
In addition, WGS test has a much faster turnaround time, which is also critical to determining the 
number of new cases infected leading to prevention of an outbreak. In order to model this time-
related variable that contributes to number of new cases infected, a prevalence-adjusting factor – 
“a” was created. Since there is a general agreement that WGS tests are faster, meaning they have 
the ability to reduce the number of new cases, the prevalence-adjusting factor – “a” was assumed 
at 2 for the SOC branch in the base case. In the SOC branch, the probability of getting infection 
was defined as “a”*prevalence. In the base case(a=2), the probability getting infection in the 
SOC branch is higher than that in the WGS branch. But in both sensitivity analyses, this 
prevalence-adjusting factor (a) was varied in the range from 0.1 to 4.  
2.6 TRANSITION PROBABILITIES 
There are several transition probabilities in our Markov model including 1) The three-month 
transition probabilities from healthy state to bacteremia, post-bacteremia or death state; 2) the 
three-month transition probabilities from bacteremia state to healthy, post-bacteremia or death 
state; 3) the three-month transition probabilities from post-bacteremia state to healthy, 
bacteremia or death state. 
Table 1 lists all the transition probabilities for a cohort of patients at age 60 in the base 
case, and most of these values were obtained from literatures 10,16. Since the age-specific 
transition probability of death was used, the transition probabilities from healthy state to death 
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state are different for different ages. In addition, the transition probability from healthy state to 
bacteremia state is based on the reported prevalence of KPC-positive K. pneumoniae and the 
percentage of its resistance to high-level disinfection.6  
Table 1. Transition probabilities for the model. 
Transition probabilities for a cohort of patients at age 60 entering the Markov model. 
2.7 COST ESTIMATES 
Table 2 lists all the estimates, the range of these estimates, and the references for cost in the base 
case. The estimated average total direct medical cost for treating bacteremia is $19350 per 
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patient, and most patients on average only require one such treatment.17 The annual direct 
medical cost for post-bacteremia patients is estimated at $5391 per patient. 18 
2.8 HRQL AND QALY ESTIMATES 
Table 2 lists all the estimates of health-related quality of life (HRQL), the range of these 
estimates, and the references for the four states. Healthy patients are considered to have perfect 
health (HRQL = 1), while HRQL of patients who are dead equals 0. The mean estimate of 
HRQL for bacteremia patients is assumed at 0.3. After discharged from the hospital, survived 
patients are moved to the “Post-bacteremia” state. Patients with bacteremia will have reduced 
quality of life after discharge 11,12. The estimate of HRQL for post-bacteremia patients is 0.68, 
which was measured with the EuroQol-5D (EQ-5D) instrument in sepsis patients after 
discharging from hospitals. 
Table 2. Costs, HRQL estimates for the model. 
Costs, HRQL estimates for patients in healthy, bacteremia, post-bacteremia, and death states. 
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3.0  RESULTS 
3.1 MODEL VALIDATION 
The red curve in Figure 3 shows the predicted survival curve for the patients with bacteremia 
from our model over 3 years after the first incidence, while the blue curve Figure 3 shows the 
observed survival curve from the hospital data over 3 years after the first incidence. The 
predicted results were consistent with the survival curve we observed from the hospital data.  
Figure 3. Predicted and observed survival curves. 
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Predicted survival curve for patients infected with bacteremia with our model over 3 
years after first incidence (red curve) and observed survival curve from hospital data over 3 years 
after first incidence (blue curve).  
3.2 BASE-CASE ANALYSIS 
A hypothetical cohort of 1000 of 60-year-old patients was simulated for ten years using the four-
state Markov model described earlier. Klebsiella pneumoniae carbapenemase (KPC)-positive K. 
pneumoniae-caused infection-related healthcare cost over ten years and quality-adjusted life year 
(QALY) were estimated for both the WGS strategy and the standard of care (SOC, high-level 
disinfection) strategy. These outcomes come from the initial infected patient and those who get 
subsequent infection from this patient. The transition probability from healthy state to bacteremia 
state per year was assumed at 1% in a hospital in the Mid-Atlantic geographic region, where the 
prevalence of the disease was 28% 6, and the cost for WGS was assumed at $100 per test based 
on market price. 
In this model, the strategy using WGS test were more cost effective than the SOC at 
UPMC Presbyterian Hospital by reducing the number of new cases infected (Table 3).  In fact, 
the SOC was dominated by the WGS test strategy given the sensitivity of the test was 0.97 and 
the specificity was 0.9919, and the prevalence-adjusting factor (a=2).   
Table 3. Results of base case analysis. 
16 
When the hospital adopted the WGS test strategy, given the sensitivity of the test was 
0.97 and the specificity was 0.99, the 10-year costs for a cohort of 1000, the QALYs, and the 
incremental cost-effectiveness ratios (ICERs) were estimated with our model. Since the hospital 
is located in the Mid-Atlantic geographic region, with the highest prevalence of KPC-positive K. 
pneumoniae in the nation at 28% and the percentage of its resistance to high-level disinfection is 
higher than 6%, the transition probability from healthy state to bacteremia state was assumed at 
0.01 (assume both the prevalence and percentage of resistance are higher in the hospital setting).6 
Under these conditions, the total 10-year mean cost for one patients was $3,281.80; while the 
mean QALYs the patient gained was 8.0819.  
In the SOC strategy, since 6.1% of the KPC-positive K. pneumoniae is resistant to high-
level disinfection there is an expectation of consistent rate of bacteremia infection for the patient 
after undergoing endoscopic retrograde cholangiopancreatography (ERCP) 6. Due to slow 
turnaround time and resistance to disinfection, the probably of healthy patients getting 
bacteremia was assumed with the prevalence-adjusting factor (a) equaled 2. The mean 10-year 
cost for one patient (including treatment cost for bacteremia and inpatient cost during the post-
bacteremia period) was $4,583.50; while the mean QALY gained was 8.0507 during that span. 
The SOC strategy (high-level disinfection) was a dominated strategy. Compared with the 
best strategy – the WGS with the sensitivity of the test was 0.97 and the specificity was 0.99. 
From cost-effectiveness analysis (CEA) perspective, the ICER was $4,173.76 per QALY. (Table 
3)
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3.3 SENSITIVITY ANALYSIS 
One-way sensitivity analysis of important model parameters (see Table 2), and the results are 
shown in Figure 4. In the WGS strategy, varying all the critical parameters resulted in similar 
cost effectiveness as in the base case. Net monetary benefits were plotted in the Figure 4. The 
WGS strategy remain the dominant strategy when variables like prevalence of KPC-positive K. 
pneumoniae, prevalence-adjusting factor (a), sensitivity and specificity of the WGS test, annual 
cost in the post-bacteremia state, WGS cost, inpatient cost in the bacteremia state, HRQL in the 
post-bacteremia state, and HRQL in the bacteremia state varied (Figure 4A and 4B). Figure 4B 
shows the same results as in Figure 4A in the absence of variables of prevalence and prevalence-
adjusting factor (a). 
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Figure 4. One-way sensitivity analyses of critical model parameters for the WGS. 
A) A tornado diagram of net monetary benefits of all variables that varied within the 
range indicated. B) A tornado diagram of net monetary benefits of all variables but 
prevalence or prevalence-adjusting factor (a). 
3.4 PROBABILISTIC SENSITIVITY ANALYSIS 
In the probabilistic sensitivity analysis (PSA), we took 1000 random values for several 
parameters simultaneously. The median ICER was -$4985.91/QALY. Figure 5 (the Incremental 
Cost-Effectiveness (CE) scatter plot) shows 89.6% of all 1,000 PSA simulations fell in the 4th 
quadrant when comparing the WGS strategy to the SOC one, meaning the SOC strategy is more 
expensive and less effective. With a willingness-to-pay (WTP) level at $50,000, none of the 
simulations had an ICER higher than the $50,000/QALY threshold (Figure 5). This calculation 
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suggests that there is 0% chance that the SOC strategy is cost effective compared with the WGS 
strategy at that threshold.  
The Cost-Effectiveness acceptability curve (Figure 6) shows that at no level of WTP the 
SOC strategy is cost effective than the WGS strategy.  
Figure 5. Incremental cost-effectiveness plot. 
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Figure 6. Cost-effectiveness acceptability curves. 
Cost-Effectiveness Acceptability Curve of the WGS strategy vs the SOC strategy. 
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4.0  DISCUSSION 
The results from the current study suggest the WGS strategy is more cost effective than the SOC 
strategy in preventing number of new cases of PC-positive K. pneumoniae in an outbreak of 
antimicrobial-resistant KPC-positive K. pneumoniae from patients undergoing endoscopic 
retrograde cholangiopancreatography in a Mid-Atlantic hospital. In our model, the SOC strategy 
is dominated by the WGS test strategy. When the sensitivity of the WGS was 0.97, the 
specificity was 0.99, and prevalence-adjusting factor (a=2) the mean total 10-year cost for one 
patient was $3,281.80; while the patient on average gained 8.0819 QALYs; while the SOC 
strategy over the same time frame had the mean 10-year cost of $4,583.50 for one patient; while 
gaining on average 8.0507 QALYs. The reduction in total healthcare cost over 10 years 
accompanied with higher total QALYs is likely due to the both high accuracy (high sensitivity 
and specificity) and faster turnaround time (high prevalence-adjusting factor for SOC strategy) of 
the WGS strategy. In one study, researchers found that the turnaround time of 72 hrs, which is 
significantly shorter than a standard diagnosis testing. 20  
Since the next generation sequencing technology becomes more and more affordable in 
recent years, some researchers have considered adopting it in the clinical setting to help detect 
infections. 20,21 In the study conducted by Cirillo et al., the authors assumed the cost for the WGS 
test is €150, very close to the assumption in this study ($100). The authors concluded that WGS 
is a rapid, cost-reasonable technique that can replace the current routine laboratory test for an 
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accurate diagnosis of drug-resistant tuberculosis, although there was no cost-effectiveness 
analysis done in the literature to this day. 20 In another study, Roe et al. also highly praised the 
WGS tests allowing precise identification or exclusion of transmission of hospital-acquired 
infections. 21 It is reasonable to speculate that one day in the near future, routine WGS tests will 
become the new SOC in the hospital setting to identify hospital-acquired infections given its 
combination of high accuracy, fast turnaround time, and affordable cost as a cost-effective 
alternative to the current SOC. 
Recent outbreak of antimicrobial-resistant KPC-positive K. pneumoniae from patients 
undergoing endoscopic retrograde cholangiopancreatography in the University of Pittsburgh 
Medical Center (UPMC) Presbyterian Hospital did lead to potentially preventable life lost, 
increase in healthcare cost, and reduce in health-related quality of life 1. Indeed, preventing 
outbreak of KPC-positive K. pneumoniae is very important in the Pittsburgh area for the 
following reasons. First, in a previous study, Nationwide SENTRY surveillance data from 2007 
to 2009 revealed that Mid-Atlantic states continued to show a significantly higher frequency of 
KPC-positive organisms than other regions in the US: 28.6% in Mid-Atlantic vs 5.5% 
nationwide.6 Geographically, Pittsburgh is within the Mid-Atlantic region, and therefore, 
prevention of dramatic higher prevalence of KPC-positive organisms is critical for public health. 
Second, KPC-positive K. pneumoniae isolates are resistant to all the commonly available 
antimicrobials, so routine high-level infection is not able to remove it.1 Third, the consequence of 
infection of KPC-positive K. pneumoniae is very serious since it can increase mortality rate and 
lower quality of life. 
It becomes clear after this study, the WGS test is particular cost-effective for a hospital 
located in Pittsburgh, a region of Mid-Atlantic. Mid-Atlantic has a five-fold increase in 
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frequency of KPC-positive organisms, and this is likely to dramatically increase the chance of 
infections in the healthcare systems. As the sensitivity analyses showed, when the prevalence of 
KPC-positive K. pneumoniae was the most sensitive factor in our model (Figure 4). However, 
even when this is the case, implementing the WGS strategy will represent a cost-effective option 
since the ICER is far less than what is considered good value for money ($50,000-
$100,000/QALY). Overall, the sensitivity analysis suggested the robustness of the current model. 
The current study has a few limitations. First, the current study was limited by few data 
of clinical information regarding mortality rate, comorbidities of patients infected with KPC-
positive K. pneumoniae. Estimates were mostly collected from cases of sepsis patients, which 
might not be accurate. Second, the utilities for patients in bacteremia state and post-bacteremia 
state were estimated separately. It would be more accurate to have these estimates from the same 
source. Third, the study lacked data for subgroup analyses.  
In conclusion, from the healthcare provider’s perspective, the whole genome sequencing 
strategy is despite its high initial costs, WGS can save lives, reduce morbidity, and be cost-
saving on the long-run compared to the SOC. 
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